Pluri (NASDAQ:PLUR) Trading Up 1.1% – Time to Buy?

Pluri Inc. (NASDAQ:PLUR)’s share price was up 1.1% during mid-day trading on Monday . The stock traded as high as $1.8466 and last traded at $1.84. Approximately 14,944 shares were traded during trading, a decline of 49% from the average daily volume of 29,346 shares. The stock had previously closed at $1.82.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 23rd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Pluri Trading Down 7.1%

The company has a market cap of $17.53 million, a PE ratio of -0.36 and a beta of 0.67. The business has a 50 day simple moving average of $1.97 and a two-hundred day simple moving average of $2.83.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.11. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.66 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent SEC filing. 16.59% of the stock is currently owned by institutional investors.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.